SCHEMBL6431834

SCHEMBL6431834

CCOC(=O)Cn1nc(-c2ccc(NC(=O)OC(C)(C)C)c(F)c2)c2c(N)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 10/20 0.57
▸ SRC P12931 8/20 0.57
▸ PTK6 Q13882 6/20 0.55
▸ KDR P35968 6/20 0.55
▸ PIK3CD O00329 5/20 0.55
▸ PIK3CA P42336 5/20 0.55
▸ PIK3CG P48736 5/20 0.55
▸ PRKDC P78527 5/20 0.55
▸ EGFR P00533 4/20 0.55
▸ PI4KB Q9UBF8 3/20 0.55
▸ BACE1 P56817 1/20 0.55
▸ FYN P06241 2/20 0.54
▸ HCK P08631 4/20 0.51
▸ PIK3CB P42338 4/20 0.51
▸ MTOR P42345 3/20 0.51
▸ EPHB4 P54760 3/20 0.51
▸ LCK P06239 1/20 0.48
▸ LYN P07948 1/20 0.48
▸ FRK P42685 1/20 0.48
▸ BLK P51451 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5801797 0.84 AURKA (0.57) SRCKDRPIK3CDPIK3CAPIK3CG
SCHEMBL5803133 0.79 CCR4 (0.49) ABL1SRCKDRPIK3CDPIK3CA
SCHEMBL5801348 0.77 ABL1 (0.57) ABL1SRCPTK6KDRPIK3CD
SCHEMBL6430376 0.77 ABL1 (0.55) ABL1SRCPTK6KDRPIK3CD
SCHEMBL5803692 0.76 KDR (0.62) ABL1SRCKDRPIK3CDPIK3CA
SCHEMBL14471393 0.76 SRC (0.73) ABL1SRCPIK3CDPIK3CAPIK3CG
SCHEMBL27088042 0.75 KDR (0.54) ABL1SRCPTK6KDRPIK3CD
SCHEMBL27088092 0.75 PIK3CD (0.55) ABL1SRCKDRPIK3CDPIK3CA
SCHEMBL5802029 0.74 ABL1 (0.51) ABL1SRCPTK6KDRPIK3CD
SCHEMBL27088073 0.73 PIK3CD (0.59) ABL1SRCKDRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
CN-1390219-A Pyrazolopyrimidines as therapeutic agents ABBOTT AG (DE) 2003-01-08 — — CN disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 ABL1 124/4885SRC 1834/4885PTK6 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback